Esperion Therapeutics, Inc. 4
4 · Esperion Therapeutics, Inc. · Filed Jul 1, 2013
Insider Transaction Report
Form 4
Aisling Capital II LP
10% Owner
Transactions
- Conversion
Common Stock
2013-07-01+1,816,475→ 1,816,475 total(indirect: By Aisling Capital II, L.P.) - Conversion
Series A Preferred Stock
2013-07-01−1,816,475→ 0 total(indirect: By Aisling Capital II, L.P.)→ Common Stock (1,816,475 underlying) - Other
Warrant to Purchase Preferred Stock
2013-07-01−497,666→ 0 total(indirect: By Aisling Capital II, L.P.)Exercise: $1.00Exp: 2018-02-12→ Series A Preferred Stock (497,666 underlying) - Other
Warrant to Purchase Common Stock
2013-07-01+71,237→ 71,237 total(indirect: By Aisling Capital II, L.P.)Exercise: $6.99Exp: 2018-02-12→ Common Stock (71,237 underlying) - Purchase
Common Stock
2013-07-01$14.00/sh+238,119$3,333,666→ 2,054,594 total(indirect: By Aisling Capital II, L.P.)
Footnotes (4)
- [F1]The Series A Preferred Stock was automatically converted into Common Stock on a 6.986-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date.
- [F2]The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling.
- [F3]The warrant is immediately exercisable.
- [F4]Upon the closing of the Issuer's initial public offering, this warrant to purchase shares of Series A Preferred Stock automatically converted on a 6.986-for-1 basis into a warrant to purchase shares of Common Stock, and the exercise price automatically adjusted accordingly. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrant and the change in exercise price.